P772: PROGNOSTIC IMPACT OF DISEASE-RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)

• C. Lesch,
• A. Kündgen,
• K. Nachtkamp,
• A. Kasprzak,
• C. Strupp,
• M. Rudelius,
• N. Gattermann,
• G. Kobbe,
• B. Hildebrandt,
• U. Germing

Affiliations

C. Lesch

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf

A. Kündgen

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf

K. Nachtkamp

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf

A. Kasprzak

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf

C. Strupp

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf

M. Rudelius

2 Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich

N. Gattermann

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf

G. Kobbe

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf

B. Hildebrandt

3 Institute of Human Genetics, Heinrich- Heine University Hospital, Düsseldorf, Duesseldorf, Germany

U. Germing

1 Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University Hospital, Düsseldorf, Duesseldorf